Next Investors logo grey

High rolling cannabis stocks continue to surge


Published 27-FEB-2017 16:01 P.M.


1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

As Finfeed discussed on Friday, ASX listed stocks leveraged to the cannabis industry were set to benefit from changed legislation regarding the use and importation of medical cannabis in Australia.

Creso Pharma (ASX: CPH) is one such player, and its shares closed at 31 cents last Friday representing a gain of nearly 35% over the previous fortnight.

However, this story is just gaining traction, and CPH’s shares surged another 10% on Monday morning.

CPH is one of the better placed players in this space in terms of benefiting from regulatory changes given that it had already negotiated a Letter of Intent with an exclusive licensed Australian distributor in Health House International for the import and sale of cannabis products.

MGC Pharmaceuticals builds on last week’s 40% gain

The other cannabis stock to rally substantially over the last fortnight was MGC Pharmaceuticals (ASX: MXC). Its shares spiked last week from 3.8 cents to hit a high of 5.1 cents, representing a gain of more than 40%.

While they finished the week at 4.6 cents, the stock has rallied more than 4% on Monday morning.

A key driver last week was the announcement that the group was on track to commence first production from its Slovenian based cannabinoid extraction facility in the second quarter of 2017.

Once operational, the company will have the ability to extract and produce high margin cannabinoids in resin form, facilitating the production of medical grade cannabis products.

It should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.